Inventor · disambiguated record
Darren H. Wakefield
Also filed as: WAKEFIELD DARREN · WAKEFIELD DARREN H
58 granted patents·20 pending applications·893 citations·filing 2003–2025
99Inventor score
Files withARROWHEAD PHARMACEUTICALS INC28ARROWHEAD MADISON INC12ROZEMA DAVID B11ROCHE MADISON INC8EMPIRICO INC6
Top patents by PatentIndex Score
78 records- 0199US8313772B2Compositions for targeted delivery of siRNAROZEMA DAVID B·Filed 2011·Granted Nov 20, 2012·159 cites·25 claims
- 0298US8658211B2Polyconjugates for in vivo delivery of polynucleotidesROZEMA DAVID B·Filed 2012·Granted Feb 25, 2014·71 cites·23 claims
- 0398US8501930B2Peptide-based in vivo siRNA delivery systemROZEMA DAVID B·Filed 2011·Granted Aug 6, 2013·180 cites·18 claims
- 0498US8137695B2Polyconjugates for in vivo delivery of polynucleotidesROZEMA DAVID B·Filed 2007·Granted Mar 20, 2012·138 cites·27 claims
- 0596US11879125B2GalNAc compositions for improving siRNA bioavailabilityEMPIRICO INC·Filed 2023·Granted Jan 23, 2024·3 cites·20 claims
- 0696US10130651B2RNAi Therapy for Hepatitis B Virus InfectionARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted Nov 20, 2018·22 cites·18 claims
- 0795US9932586B2Compositions and methods for inhibiting gene expression of LPAARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted Apr 3, 2018·9 cites·39 claims
- 0895US9796756B2Galactose cluster-pharmacokinetic modulator targeting moiety for siRNAARROWHEAD MADISON INC·Filed 2015·Granted Oct 24, 2017·24 cites·20 claims
- 0995US8802773B2In vivo polynucleotide delivery conjugates having enzyme sensitive linkagesROZEMA DAVID B·Filed 2013·Granted Aug 12, 2014·12 cites·22 claims
- 1095US8426554B2In vivo polynucleotide delivery conjugates having enzyme sensitive linkagesROZEMA DAVID B·Filed 2011·Granted Apr 23, 2013·47 cites·14 claims
- 1194US12188017B2Compositions and methods for inhibiting gene expression of alpha-1 antitrypsinARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Jan 7, 2025·1 cites·12 claims
- 1294US11517584B2RNAi agents for Hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Dec 6, 2022·2 cites·58 claims
- 1393US10662427B2Compositions and methods for inhibiting gene expression of LPAARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted May 26, 2020·6 cites·39 claims
- 1492US11590156B2RNAi agents for hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Feb 28, 2023·2 cites·37 claims
- 1592US10780108B2RNAi agents for Hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Sep 22, 2020·5 cites·67 claims
- 1692US10246709B2Targeting ligands for therapeutic compoundsARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Apr 2, 2019·10 cites·27 claims
- 1792US9803205B2Compositions and methods for inhibiting gene expression of factor XIIARROWHEAD MADISON INC·Filed 2016·Granted Oct 31, 2017·9 cites·25 claims
- 1891US11384355B2Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsinARROWHEAD PHARMACEUTICALS INC·Filed 2019·Granted Jul 12, 2022·3 cites·23 claims
- 1990US7442764B2Reversible modification of amine-containing compoundsMIRNS BIO CORP·Filed 2005·Granted Oct 28, 2008·10 cites·20 claims
- 2090US7348453B2Labile linkage for compound delivery to a cellMIRUS BIO CORP·Filed 2004·Granted Mar 25, 2008·24 cites·7 claims
- 2190US7019113B2Reversible modification of membrane interactionMIRUS BIO CORP·Filed 2003·Granted Mar 28, 2006·38 cites·18 claims
- 2290US2025197861A1Compositions and methods for inhibiting gene expression of alpha-1 antitrypsinARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2389US10806750B2RNAi therapy for hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Oct 20, 2020·3 cites·9 claims
- 2488US10006025B2Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsinARROWHEAD MADISON INC·Filed 2015·Granted Jun 26, 2018·5 cites·25 claims
- 2588US9345775B2Compositions for targeted delivery of siRNAARROWHEAD MADISON INC·Filed 2015·Granted May 24, 2016·5 cites·27 claims
- 2687US10308941B2Compositions and methods for inhibiting gene expression of factor XIIARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Jun 4, 2019·4 cites·26 claims
- 2787US7094605B2Formation of polyampholytes in the presence of a polyionMIRUS BIO CORP·Filed 2005·Granted Aug 22, 2006·6 cites·19 claims
- 2887US2025243485A1Targeting Ligands For Therapeutic CompoundsARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2986US10927373B2Compositions and methods for inhibiting gene expression of Hif2alphaARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Feb 23, 2021·2 cites·20 claims
- 3086US9976141B2Compositions and methods for inhibiting gene expression of Hif2alphaARROWHEAD MADISON INC·Filed 2016·Granted May 22, 2018·5 cites·32 claims
- 3186US9011919B2Compositions for targeted delivery of siRNAROZEMA DAVID B·Filed 2012·Granted Apr 21, 2015·7 cites·22 claims
- 3286US2025115907A1Compositions and methods for inhibiting gene expression of lpaARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3385US8211468B2Endosomolytic polymersROZEMA DAVID B·Filed 2006·Granted Jul 3, 2012·5 cites·2 claims
- 3485US8008355B2Endosomolytic poly(vinyl ether) polymersROCHE MADISON INC·Filed 2008·Granted Aug 30, 2011·5 cites·14 claims
- 3585US7816337B2Reversible attachment of a membrane active polymer to a polynucleotideROCHE MADISON INC·Filed 2004·Granted Oct 19, 2010·12 cites·13 claims
- 3685US7682626B2Polyvinylethers for delivery of polynucleotides to mammalian cellsROCHE MADISON INC·Filed 2004·Granted Mar 23, 2010·10 cites·15 claims
- 3784US9526796B2Peptide-based in vivo siRNA delivery systemARROWHEAD MADISON INC·Filed 2015·Granted Dec 27, 2016·3 cites·20 claims
- 3884US9249179B2Galactose cluster-pharmacokinetic modulator targeting moiety for siRNAHADWIGER PHILIPP·Filed 2011·Granted Feb 2, 2016·10 cites·5 claims
- 3983US9107957B2Peptide-based in vivo siRNA delivery systemARROWHEAD MADISON INC·Filed 2013·Granted Aug 18, 2015·5 cites·14 claims
- 4082US12258564B2GalNAc compositions for improving siRNA bioavailabilityEMPIRICO INC·Filed 2023·Granted Mar 25, 2025·0 cites·20 claims
- 4181US8933047B2Poly(acrylate) polymers for in vivo nucleic acid deliveryWAKEFIELD DARREN H·Filed 2012·Granted Jan 13, 2015·3 cites·20 claims
- 4280US2023355651A1Rnai agents for hepatitis b virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4379US7985406B2Membrane active heteropolymersROCHE MADISON INC·Filed 2008·Granted Jul 26, 2011·2 cites·21 claims
- 4479US2023355654A1Rnai therapy for hepatitis b virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4578US12258563B2Modified oligonucleotidesEMPIRICO INC·Filed 2023·Granted Mar 25, 2025·0 cites·19 claims
- 4677US7071163B2Compounds for targeting hepatocytes in vivoMIRUS BIO CORP·Filed 2003·Granted Jul 4, 2006·7 cites·20 claims
- 4776US12116573B2Targeting ligands for therapeutic compoundsARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Oct 15, 2024·0 cites·3 claims
- 4876US9803201B2Disulfide-containing alkyne linking agentsARROWHEAD MADISON INC·Filed 2016·Granted Oct 31, 2017·1 cites·14 claims
- 4976US8932572B2Poly(vinyl ester) polymers for in vivo nucleic acid deliveryWAKEFIELD DARREN H·Filed 2012·Granted Jan 13, 2015·4 cites·20 claims
- 5076US7470539B2Formation of polyampholytes in the presence of a polyionROCHE MADISON INC·Filed 2005·Granted Dec 30, 2008·1 cites·17 claims
Showing the top 50 of 78 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →